Manager 2
Tarsus Pharmaceuticals
Manager 2
Tarsus Pharmaceuticals
Develops FDA-approved ophthalmic therapies
Hi Tarsan!
Thanks for your interest in this position. Please review the details and if role and if it's something that could match your career goals, connect with your current manager and HRBP to discuss if your experience and skills line up. If everything is a go, please apply and the Talent Acquisition team will contact you for an interview so we can also get to know you better.
- Your Human Resources Team
About the Role
Join us in advancing our pipeline to address a number of diseases across therapeutic categories, including eye care and other conditions with high unmet need.
This role will lead program management for a late-stage (Phase 2b/3 through regulatory submission, approval, and launch readiness) drug development program. The Manager II, Program Management partners closely with the Program Team Lead and Development Core Team to drive cross-functional program strategy, integrated development planning, and disciplined execution through pivotal trial readouts, regulatory filing, approval, and commercialization.
Let’s talk about some of the key responsibilities of the role:
Factors for Success:
A Few Other Details Worth Mentioning:
At Tarsus, we understand the importance of attracting and retaining top talent. The expected base pay range for this position is $134,200 - $188,000 plus bonus, stock equity, and comprehensive benefits. The base pay range reflects the target range for this position, but individual pay will be determined by additional factors such as job-related skills, experience and relevant education or training. Our benefits include health, dental and vision insurance benefits to ensure your well-being. We believe in work-life balance and offer generous paid time off, including vacation, holidays, and personal days. For more details regarding Tarsus benefits, please visit: https://eb.alliant.com/26tarsusbenefitssnapshot.
#LI-Remote
Develops FDA-approved ophthalmic therapies
Tarsus Pharmaceuticals develops and markets treatments for eye care and infectious diseases, including XDEMVY (lotilaner ophthalmic solution 0.25%), an FDA-approved eye drop for Demodex Blepharitis. The product is applied as a medicated eye drop to kill Demodex mites and relieve eyelid inflammation. The company differentiates itself with a focused ocular/infectious-disease portfolio, an FDA-approved therapy, and active partnerships to expand its research and reach. Its goal is to address unmet medical needs, grow its product lineup through commercialization, and pursue new indications in eye care and infectious diseases.
Explore more opportunities at Tarsus Pharmaceuticals